Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain

The Puzzling Rise and Fall of a Dark-Horse Alzheimer's Drug

(2010) G. Miller   SCIENCE

Structural Model for the Binding Sites of Allosterically Potentiating Ligands on Nicotinic Acetylcholine Receptors

(2009) Edgar Luttmann et al.   ChemMedChem

Single-channel study of the binding-gating coupling in the slowly desensitizing chimeric α7-5HT3A receptor

(2009) José Antonio Bernal et al.   FEBS LETTERS

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy

(2009) Alfred Maelicke et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Alpha7 neuronal nicotinic receptors: The missing link to understanding Alzheimer’s etiopathology?

(2009) Merouane Bencherif et al.   MEDICAL HYPOTHESES

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design

(2008) G. Sharma et al.   CURRENT MEDICINAL CHEMISTRY

Potentiation of  7 nicotinic acetylcholine receptors via an allosteric transmembrane site

(2008) G. T. Young et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Competitive Potentiation of Acetylcholine Effects on Neuronal Nicotinic Receptors by Acetylcholinesterase-Inhibiting Drugs

(2003) Ruud Zwart et al.   JOURNAL OF NEUROCHEMISTRY